Rating Change
Cantor Fitzgerald reiterated its Overweight rating on Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) on October 02, 2026.
reiterateNASDAQ:ARTV
Cantor Fitzgerald Reiterates Overweight Rating on Artiva Biotherapeutics, Inc. (ARTV)
Cantor Fitzgerald reiterated its Overweight rating on Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) on October 02, 2026.
At publication ·
What changed
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) · reiterate
- Firm
- Cantor Fitzgerald
- Rating
- Overweight to Overweight
- Price at event
- $7.03
- Market capitalization
- $142.9M
At a glance
Key takeaways
- Cantor Fitzgerald reiterated an Overweight rating on Artiva Biotherapeutics (ARTV) on October 2, 2026, with the stock trading at $7.03 and a market capitalization of $142.9 million.
Market Context
Artiva Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $7.03 with a market capitalization of $142.9M.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Artiva Biotherapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Artiva Biotherapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 02, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 08, 2026 | Needham | Buy | N/A |
| May 12, 2026 | Needham | Buy | N/A |
| May 11, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 11, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ARTV Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ARTV?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Artiva Biotherapeutics, Inc. (NASDAQ:ARTV). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ARTV forecast page.